The future prospects of oxazolidinones

IDrugs

Volumn 6, Issue 3, 2003, Pages 240-245

  Johnson, Alan P ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

Antibacterial resistance; AZD 2563; Linezolid; Oxazolidinones

Indexed keywords

1,3,4 OXADIAZOLEPHENYLOXAZOLIDINONE DERIVATIVE; 1,3,4 THIADIAZOLEPHENYLOXAZOLIDINONE DERIVATIVE; 4 ACYLAMINOPHENYLOXAZOLIDINONE DERIVATIVE; 4 SULFIDE OXAZOLIDINONE DERIVATIVE; 4 SULFOXIDE 3 FLUOROPHENYLOXAZOLIDINONE DERIVATIVE; 4 THIOUREA PHENYLOXAZOLIDINONE DERIVATIVE; 4 UREA PHENYLOXAZOLIDINONE DERIVATIVE; ANTIINFECTIVE AGENT; AZOLOBENZOXAZEPINYLOXAZOLIDINONE DERIVATIVE; AZTREONAM; BETA LACTAM ANTIBIOTIC; DA 7867; FLUCLOXACILLIN; LINEZOLID; MCB 1033; MCB 116; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PNU 288034; POSIZOLID; PYRIDAZINE PHENYLOXAZOLIDINONE DERIVATIVE; RWJ 334181; RWJ 337813; TRICYCLIC OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL; VANCOMYCIN; VRC 3782; VRC 4228;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION; LABORATORY TEST; LONG TERM CARE; MORAXELLA CATARRHALIS; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTOPENIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; HUMANS; OXAZOLIDINONES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037842721     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Woodford N, Livermore DM. Can we beat MRSA now we know its genome sequence? Lancet Infect Dis (2001) 1: 9-10.
2. European antimicrobial resistance surveillance system: Annual Report 2001.
3. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK et al: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis (1999) 28: 1206-1211.
4. Chen DK, McGreer A, De Azavedo JC, Low DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med (1999) 341:223-229.
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 40: 135-136.
6. Staphylococcus aureus resistant to vancomycin - United States. Morbid Mortal Weekly Rep (2002) 51:565-567. First report of S aureus with high-level resistance to glycopeptides.
7. Centers for Disease Control and Prevention: Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morbid Mortal Weekly Rep (2002) 51:902. A second isolate of S aureus with high-level resistance to glycopeptides. reported ∼ 3 months after the first case report.
8. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, Bartholomew PT, Gregory WA, Forbes M: Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother (1987) 31: 1791-1797.
9. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother (1996) 40:839-845.
10. Gravestock MB, Betts MJ, Chawner E, Dawson L, McGregor A, Mills SD, Wilson RG, Woods L, Wookey A: In vivo studies of novel oxazolidinones with O- and N-linked C-5 heterocyclic side-chains, including AZD2563. 41st ICAAC Meeting, Chicago, IL, USA (2001): ABS 1023.
11. Arundel PA: The new oxazolidinone AZD2563: Physiologically-based pharmacokinetic extrapolation to man. 41st ICAAC Meeting, Chicago, IL, USA (2001): Abs 1039.
12. AstraZeneca plc: AstraZeneca R&D pipeline: NCEs 25 July 2002. Company World Wide Website (2002) July 25. www.astrazeneca.com
13. Jones RN, Johnson DM, Erwin ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother (1996) 40:720-726.
14. Johnson AP, Warner M, Livermore DM: Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother (2000) 45:225-230.
15. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D: In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci. J Antimicrob Chemother (2002) 50:271-276.
16. Peric M, Lin G, Clark CL, Jacobs MR, Appelbaum PC: Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents. J Antimicrob Chemother (2002) 50:95-100.
17. Anderegg TR, Biedenbach DJ, Jones RN: In vitro evaluation of AZD2563, a new oxazolidinone, tested against β-haemolytic and viridans group streptococci. J Antimicrob Chemother (2002) 49:1019-1021.
18. Jones RN, Biedenbach DJ, Anderegg TR: In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. Diagn Microbiol Infect Dis (2002) 42: 119-122.
19. Johnson AP, Warner M, Malnick H, Livermore DM: Activity of AZD2563 against Corynebacterium jeikeium and other Corynebacterium spp. 42nd ICAAC Meeting, San Diego, CA, USA (2002): Abs F-1304.
20. Bowerstock TL, Salmon SA, Portis ES, Prescott JF, Robison DA, Ford CW, Watts JL: MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals. Antimicrob Agents Chemother (2000) 44:1367-1369.
21. Rodríguez JC, Ruiz M, López M, Royo G: In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents (2002) 20:464-467.
22. Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW: Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother (2001) 45:764-767.
23. Ednie LM, Jacobs MR, Appelbaum PC: Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother (2002) 50:101-105.
24. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother (1998) 42:3251-3255. Paper giving insight into the novel mode of action of oxazolidinones.
25. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, Hafkin B: Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother (2000) 44:3408-3413. Clinical trial demonstrating the efficacy of linezolid.
26. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2002) 34:1481-1491. Clinical trial demonstrating the efficacy of linezolid.
27. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, Crouch CW, Hafkin B, Glick HA: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy (2001) 21:263-274.
28. Rubinstein E, Cammarata S, Oliphant T, Wunderink R: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis (2001) 32:402-412. Clinical trial demonstrating the efficacy of linezolid.
29. Chien JW, Kucia ML, Salata RA: Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis (2000) 30:146-151.
30. Moise PA, Forrest A, Birmingham MC, Schentag JJ: The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother (2002) 50:1017-1026.
31. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S: Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis (2001) 32:1373-1375.
32. Rao N, White GJ: Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis (2002) 35:902-904.
33. Ruiz ME, Guerrero IC, Tuazon CU: Endocarditis caused by methicillin-resistant Staphylococcus aureus: Treatment failure with linezolid. Clin Infect Dis (2002) 35:1018-1020.
34. Melzer M, Goldsmith D, Gransden W: Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteraemias. Clin Infect Dis (2000) 31:208-209.
35. Till M, Wixson RL, Pertel PE: Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis (2002) 34:1412-1414.
36. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Killburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother (1996) 40:839-845.
37. Woodford N, Stockdale M, Tysall L, Johnson A, Livermore D: Enterococcal and staphylococcal resistance to the new oxazolidinone AZD2563 is difficult to select in vitro. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1306.
38. Zurenko GE, Todd WM, Hafkin B, Meyers B, Kauffman C, Bock A, Slightom J, Shinabarger D: Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. 39th ICAAC Meeting, San Francisco, CA, USA (1999):Abs 848. First report of resistance to linezolid in the clinical isolates of enterococci.
39. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357:1179. Further report of resistance to linezolid in the clinical isolates of enterococci.
40. Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med (2002) 346:867-869. Report of inter-patient spread of linezolid-resistant enterococci.
41. Johnson AP, Tysall L, Stockdale MW, Woodford N, Kaufmann ME, Warner M, Livermore DM, Asboth F, Allerberger FJ: Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis (2002) 10:751-754. Report of cross-resistance between the oxazolidinones linezolid AZD-2563.
42. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP: Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother (2002) 50:743-746.
43. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ: Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis (2002) 42:137-139.
44. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358:207-208. First report of resistance to linezolid in a clinical isolate of MRSA.
45. Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, Robbins M: Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (2003) 51:186-188. Second report of resistance to linezolid in a clinical isolate of MRSA (the first isolate seen in the UK).
46. Enne V, Howe RA, Walsh TR, Mutnick AH, Jones RN: Initial descriptions of linezolid resistance in S. epidermidis and Streptococcus oralis: Report from the SENTRY antimicrobial surveillance program. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs LB-10.
47. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE: Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 235 rRNA. 38th ICAAC Meeting, San Diego, CA, USA (1998):Abs C-104. Report giving insight into mechanism of resistance to linezolid.
48. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA: Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother (2001) 45:2154-2156. Report giving further insight into mechanism of resistance to linezolid.
49. Gordeev MF, Singh U, Luehr GW, Gadwood RC, Jain R, Hackbarth CJ, Lopez S, Trias J, Patel DV: Acyclic C-group oxazolidinones: Antimicrobial 4-acylamino, 4-urea and 4-thiourea phenyloxazolidinones. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-11045.
50. Luehr GW, Gordeev MF, Gadwood RC, Hackbarth CJ, Lopez S, Trias J, Patel DV: Acyclic C-group oxazolidinones: Antimicrobial activity of novel 4-sulfide and 4-sulfoxide 3-fluorophenyl oxazolidinones. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1044.
51. Gordeev MF, Luehr GW, Gardwood RR, Fan P, Hackbarth CJ, Lopez S, Trias J, Patel DV: Antimicrobial activity of novel 1,3,4-thiadiazole, 1,3,4-oxadiazole, and benzimidazole phenyloxazolidinones. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1046.
52. Gordeev MF, Luehr GW, Gadwood RC, Scott CR, Hackbarth CJ, Lopez S, Trias J, Friis JM, Williams MG, Hosley JD, Courtney M et al: 4-Amido phenyloxazolidinone thioamides: Antimicrobial activity and pharmacokinetics in rat. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1047.
53. Zhou J, Mortell K, Bore R, Gadwood RC, Wu C, Gomez M, Hackbarth CJ, Yuan Z, Trias J, Patel DV, Gordeev MF: Combinatorial lead optimization of oxazolidinones: In vitro activity of novel 5-amidomethyl thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1319.
54. Ciske FL, Barbachyn MR, Munesada K, Dolak L, Seest EP, Watt, Adams WJ, Friis JM, Ford CW, Zurenko GE, Genin MJ: Stereochemical effects on the antibacterial activity of 2-methyl-tetrahydroquinolinyl and 3-methyl-dihydrobenzoxazinyl oxazolidinones. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1043.
55. Friis JM, Palandra J, Courtney M, Hosley JD, Jensen JL, Smith DP, Biermacher JJ, Ouding RJ, Jones BW, Norris LR, Vandegiessen TL et al: Pharmacokinetics of an oxazolidinone antibacterial, PNU-288034, in the rat and dog. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1341.
56. Luehr GW, Wang S, Hackbarth CJ, Gomez M, Trias J, Patel DV, Gordeev MF: Novel antimicrobial pyridazine phenyloxazolidinones. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1320.
57. Sitaram Kumar M, Das J, Mamidi Rao NVS, Subrahmanyam D, Sastry TVR, Prasad Narasimhulu C, Sarnaik HM, Ravikanth B, Iqbal J, Rajagopalan R: Antibacterial potential of new azolo benzoxazepinyl oxazolidinones - A SAR study. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1051.
58. Gopalakrishnan B, Khandelwal A, Rajjak SA, Selvakumar N, Dass J, Trehan, J. Iqbal, M, Kumar S. Three-dimensional quantitative structure activity relationship (3D-QSAR) studies: CoMFA and CoMSIA of tricyclic oxazolidinones as antibacterials. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1326.
59. Foleno BD, Goldschmidt R, Licata L, Montenegro D, Paget S, Weidner-Wells M, Wira E, Macielag M, Bush K: In vitro antibacterial activity of the pyrrolopyridine-substituted oxazolidinones RWJ-334181 and RWJ-337813. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-1049.
60. Im W, Lee T, Cho J, Choi S, Rhee J: In vitro and in vivo studies of hetero-ring substituted pyridine containing oxazolidinone derivatives, including DA-7867. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1311.
61. Choi S, Lee T, Im W, Cho J, Kim D, Rhee J, Kim W: In vitro antibacterial activity of DA-7867, a new oxazolidinone. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1313.
62. Locher HH, Specklin J, Borer Y, Brohammer S, Schroeder S, Sigwalt C, Hubschwerlen C: Synthesis and antibacterial action of novel quinolone-linked oxazolidinones. 42nd ICAAC Meeting, San Diego, CA, USA (2002):Abs F-1317.